Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.
Kidney Replacement Disorder
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Platelet Function, Whole Blood Coagulation and Fibrinolysis During Continuous Renal Replacement Therapy - a Comparison of Citrate and Heparin Anticoagulation|
- Filter life time of continuous renal replacement therapy [ Time Frame: Individual time point, standardized ] [ Designated as safety issue: Yes ]Filter life time measured in hours of duration of continuos renal replacement therapy, filter life time end, when system clotts.
- Activation of coagulation [ Time Frame: beginning of hemodialysis, 1,2,4,12,24,28,72 hours after start of hemodialysis ] [ Designated as safety issue: No ]blood samples for multiplate, rotem and systemic coagulation paramters
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01276392
|Interdisciplinary Operative Intensive Care Unit, University Hospital Duesseldorf|
|Duesseldorf, NRW, Germany, 40225|
|Principal Investigator:||Detlev Kindgen-Milles, Professor,MD||Department of Anesthesiology, University Hospital Duesseldorf, Heinrich Heine University|